Adtalem Global Education Stock Rises 6.5% to $98.92

Written by Emily J. Thompson, Senior Investment Analyst

ATGE-2.52%

Updated: Dec 15 2025

0mins

Adtalem Global Education is up 6.5%, or $6.04 to $98.92.

ATGE

$115.22+Infinity%1D

Analyst Views on ATGE

Wall Street analysts forecast ATGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATGE is 163.67 USD with a low forecast of 158.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 118.200

Low

158.00

Averages

163.67

High

170.00

Current: 118.200

Low

158.00

Averages

163.67

High

170.00

Baird

Outperform -> NULL

downgrade

$169 -> $163

2025-10-31

Reason

Baird

Price Target

$169 -> $163

AI Analysis

2025-10-31

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on Adtalem Global Education to $163 from $169 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results which saw guidance held despite execution missteps pressuring Chamberlain post licensure.

Barrington

NULL

Outperform

maintain

$150 -> $170

2025-10-15

Reason

Barrington

Price Target

$150 -> $170

2025-10-15

maintain

NULL

Outperform

Reason

Barrington raised the firm's price target on Adtalem Global Education to $170 from $150 and keeps an Outperform rating on the shares ahead of the fiscal Q1 report on October 30. Demand for healthcare professionals, which represents 90% of Adtalem's enrollment, will continue to outpace supply for the foreseeable future, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATGE

Unlock Now

Barrington

Alexander Paris

Outperform

maintain

$140 -> $150

2025-08-08

Reason

Barrington

Alexander Paris

Price Target

$140 -> $150

2025-08-08

maintain

Outperform

Reason

Barrington analyst Alexander Paris raised the firm's price target on Adtalem Global Education to $150 from $140 and keeps an Outperform rating on the shares after the company reported Q4 results that "significantly topped expectations" and gave initial FY26 guidance that was also "well ahead of the consensus." Given Adtalem's focus on nursing and healthcare, the firm believes shares deserves a premium multiple as it expects demand for healthcare professionals will continue to outpace supply "for the foreseeable future."

Baird

Jeffrey Meuler

Outperform

maintain

$143 -> $169

2025-08-08

Reason

Baird

Jeffrey Meuler

Price Target

$143 -> $169

2025-08-08

maintain

Outperform

Reason

Baird analyst Jeffrey Meuler raised the firm's price target on Adtalem Global Education to $169 from $143 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results and 2026 guidance which was above consensus with strong growth.

About ATGE

Adtalem Global Education Inc. is a provider of healthcare education in the United States, preparing a diverse workforce with academic programs. Its healthcare programs include nursing, medicine, veterinary medicine, social and behavioral sciences and more. Its segments include Chamberlain, Walden, and Medical and Veterinary. Chamberlain segment offers degree and certificate programs in the nursing and health professions postsecondary education industry. Walden segment offers degree and certificate programs, including those in nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice. Medical and Veterinary segment offers degree and certificate programs in the medical and veterinary postsecondary education industry. This segment includes American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.